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Avian inﬂuenza H5, H7 and H9 viruses top the World Health Organization's (WHO) list of subtypes with
the greatest pandemic potential. Here we describe a recombinant virus-like particle (VLP) that co-
localizes hemagglutinin (HA) proteins derived from H5N1, H7N2, and H9N2 viruses as an experimental
vaccine against these viruses. A baculovirus vector was conﬁgured to co-express the H5, H7, and H9
genes from A/Viet Nam/1203/2004 (H5N1), A/New York/107/2003 (H7N2) and A/Hong Kong/33982/2009
(H9N2) viruses, respectively, as well as neuraminidase (NA) and matrix (M1) genes from A/Puerto Rico/8/
1934 (H1N1) virus. Co-expression of these genes in Sf9 cells resulted in production of triple-subtype VLPs
containing HA molecules derived from the three inﬂuenza viruses. The triple-subtype VLPs exhibited
hemagglutination and neuraminidase activities and morphologically resembled inﬂuenza virions.
Intranasal vaccination of ferrets with the VLPs resulted in induction of serum antibody responses and
efﬁcient protection against experimental challenges with H5N1, H7N2, and H9N2 viruses.
& 2013 Elsevier Inc. All rights reserved.Introduction
Avian inﬂuenza represents an acute threat to public health
(Morens and Fauci, 2012; Palese, 2006; Yen and Webster, 2009).
With an increasing number of infections of highly pathogenic
avian inﬂuenza (HPAI) of the H5N1 subtype, there is a concern that
this virus could cause a pandemic (Kang et al., 2009; Morens and
Fauci, 2012). In addition to H5N1, other potentially pandemic
viruses of avian origin exist. The H7N7 and H7N2 viruses caused
human infections in the past indicating the potential threat posed
by H7 subtype viruses (Belser et al., 2008; Pappas et al., 2007).
Avian H9N2 inﬂuenza was also identiﬁed as a human pathogen
(Blanco et al., 2013; Pushko et al., 2005; Yen and Webster, 2009).
Frequent genetic changes, multiple strains capable of reassort-
ment, and the possibility of genetic manipulation represent
challenges for inﬂuenza vaccine development (Morens and Fauci,
2012; Palese, 2004). Prediction of pandemic virus is a challenging
task; therefore, a prepandemic vaccine that induces immunity to
multiple potentially pandemic subtypes can be important for
pandemic preparedness including vaccine stockpiling options
(Rebmann and Zelicoff, 2012). This is emphasized by the outbreak
of H7N9 virus in China. In the case of a pandemic, suchll rights reserved.
shko).prepandemic vaccines could decrease the severity of disease and
save lives during a pandemic until a speciﬁc pandemic vaccine is
made (Oxford et al., 2006; Palese, 2006). However, for ﬁnancial
reasons it is not feasible to make a multivalent prepandemic vaccine
using current commercial technology. Classic trivalent inactivated
vaccines represent mixtures of inactivated H1N1, H3N2, and inﬂuenza
B viruses (Kang et al., 2009; Palese, 2006; Pushko, 2009). Each virus is
grown separately in fertilized eggs, inactivated, and then combined
with two other strains to make a trivalent vaccine. Live attenuated
inﬂuenza vaccines are also initially prepared in eggs and then blended
to produce a trivalent vaccine (Hussain et al., 2010). Preparation of
pandemic vaccines is costly and the need for individual preparation of
vaccines for multiple strains increases the cost of a trivalent vaccine.
The use of eggs in vaccine production is another weakness. Although
the ﬁrst cell-based and recombinant subunit inﬂuenza vaccines have
been introduced (Plosker, 2012; Treanor et al., 2011) and recently
approved by the regulatory agencies, the majority of inﬂuenza
vaccines are still made in eggs and in the event of an outbreak of
avian inﬂuenza or other disease that affects chicken ﬂocks, the supply
of vaccine could be threatened.
Recombinant virus-like particles (VLPs) have been recently shown
as a promising vaccine approach for inﬂuenza (Galarza et al., 2005;
Kang et al., 2009; Perrone et al., 2009; Pushko et al.; Pushko et al.,
2005; Quan et al.; Ross et al., 2009). Recombinant VLPs are produced
by using cell culture methods and do not require egg-based
technology for the production. In a recent study, we described novel
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envelope (Pushko et al., 2011). By immunoelectron microscopy, we
have shown that multiple subtypes of HA can co-localize within VLP
and that such multi-subtype VLPs induce highly protective immune
responses against multiple strains of inﬂuenza when administered
intramuscularly (i.m.) (Pushko et al., 2011). In the current study, we
conﬁgured a triple-subtype VLP to contain the H5, H7, and H9
proteins derived from three potentially pandemic inﬂuenza viruses
and evaluated immunogenicity and efﬁcacy of such H5/H7/H9 VLPs
following intranasal (i.n.) vaccination. We demonstrate that i.n.
vaccination with the H5/H7/H9 triple-subtype VLP induced immune
responses and protected ferrets from experimental challenges with
three avian inﬂuenza viruses. Potential advantages of multi-subtype
VLPs for pandemic preparedness strategies are discussed.Results
Preparation of triple-subtype H5/H7/H9 VLPs
For preparation of triple-subtype VLPs, the HA proteins were
derived from three avian-origin inﬂuenza viruses, H5N1, H7N2 and
H9N2. The HPAI H5N1 virus, VN/04 of clade 1, was isolated from a
fatal human case and caused 100% lethality in ferrets (Maines
et al., 2005). The H7N2 virus, NY/03, was isolated from a hospi-
talized patient that recovered and subsequently found to replicate
efﬁciently in the upper respiratory tract of ferrets (Belser et al.,
2008; Ostrowsky et al., 2012). The H9N2 virus, HK/09 of G1 clade,
was originally isolated from a nasopharyngeal aspirate of an adult
female patient (Cheng, 2010).
In order to prepare triple-subtype H5/H7/H9 VLP vaccine, the
rBV vector was made that co-expressed H5, H7, H9, as well as NA
and M1 genes (Fig. 1a). The H5, H7 and H9 genes encoded
polypeptides of 568 aa, 552 aa, and 560 aa in length with pre-
dicted average molecular masses of 64.5 kilodalton (kDa), 61.5 kDa
and 62.9 kDa, respectively. The NA and M1 were 454 aa and 252 aa
in length and had expected molecular masses of 50.1 kDa and
27.9 kDa, respectively. Both NA and M1 have been previously
shown to be important structural constituents of inﬂuenza VLPsH7 H5 H9 NA M
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Fig. 1. Preparation of triple-subtype VLPs that co-localize HA proteins from H5, H7 an
subtype VLPs in Spodoptera frugiperda (Sf9) cells. Inﬂuenza HA gene sequences were deriv
were from PR8 virus (see text for virus abbreviations). The H5, H7, H9, NA, and M1 genes
expressed from its own polyhedrin (Ph) promoter. (b) Schematic depiction of triple-subt
Locations of inﬂuenza proteins and SeeBlue Plus2 molecular weight standards are show
viruses followed by alkaline phosphatase-conjugated anti-ferret goat IgG (H+L). (c) Im
expressing multiple HA subtypes (left) or uninfected control Sf9 cells (right). Indicated
antigens in infected and uninfected control Sf9 cells.(Pushko et al., 2011, 2005) and therefore were included in the
expression construct. The NA and M1 genes were derived from
PR8 virus, which is standard strain used in commercial reassortant
vaccines. For preparation of VLPs, Sf9 cells were infected with rBV
at an MOI of 3 to allow expression of H5, H7, H9, NA, and M1
genes, and the VLPs were harvested from culture supernatant.
Characterization of triple-subtype VLPs
Triple-subtype H5/H7/H9 VLPs were concentrated 100-fold and
partially puriﬁed by ultracentrifugation. The presence of H5, H7,
and H9 proteins in VLPs was conﬁrmed by SDS-PAGE and western
blot (Fig. 1b), as well as by IFA in Sf9 cells infected with
recombinant BV (Fig. 1c). The HAs within VLPs represented
uncleaved HA0 polypeptides of approximately 62–64 kDa, while
the NA was not detected by western blot suggesting low level of
cross-reactivity with the H5N1-, H7N2-, and H9N2-speciﬁc anti-
sera used in western blot. A band of approximately 25 kDa
corresponding to M1 protein was detected by western blot with
H9N2-speciﬁc antiserum, but not with H5N1 or H7N2 antisera. By
gel staining, a band of approximately 40 kDa was observed, which
was not detectable by antisera in western blot and could represent
an rBV- or Sf9 cell-derived contaminant.
The ability of H5/H7/H9 VLPs to agglutinate turkey RBCs was
conﬁrmed by hemagglutination assay (Fig. 2a). For hemagglutina-
tion assay, dilutions of VLPs were mixed with turkey RBCs recom-
mended by theWHO as a reagent for animal inﬂuenza diagnosis and
surveillance (WHO, 2012b). The complete hemagglutination activity
at the titer of 1:2048 of unconcentrated VLPs conﬁrmed that the
incorporated HA proteins retained their stability and binding activ-
ities (Fig. 2a). The size and morphology of triple-subtype H5/H7/H9
VLPs were further examined by negative-staining transmission
electron microscopy. The H5/H7/H9 VLPs were identiﬁed as largely
spherical, typical inﬂuenza-like enveloped particles approximately
90–120 nm in diameter and characteristic prominent spikes pro-
truding from the VLP envelope (Fig. 2b).
The functional NA enzymatic activity of VLPs was conﬁrmed by
using standard ﬂuorescence-based inﬂuenza neuraminidase assay
(Fig. 2c).1 
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d H9 subtype viruses. (a) Recombinant baculovirus (rBV) for expression of triple-
ed from VN/04 (H5N1), NY/03 (H7N2), and HK/09 (H9N2) viruses. NA and M1 genes
were combined within recombinant rBV in a tandem fashion so that each gene was
ype VLPs and detection of HA proteins within VLPs by SDS-PAGE and western blot.
n. Western blot was done using ferret antisera against VN/04, NY/03, and HK/09
munoﬂuorescence assay (IFA) of Sf9 cells infected with recombinant baculovirus
subtype-speciﬁc ferret antisera were used for evaluating expression of respective
Fig. 2. Characterization of triple-subtype VLPs, by (a) hemagglutination assay, (b) negative staining transmission electron microscopy and (c) neuraminidase enzyme assay.
(a) VLPs were harvested from the culture medium of rBV-infected Sf9 cells on day 3. VLPs were concentrated 100-fold, partially puriﬁed by 20% step sucrose gradient
ultracentrifugation, and resuspended in PBS buffer. Hemagglutination test was done on unconcentrated VLPs using turkey erythrocytes. Arrow indicates the HA titer. (b) For
transmission electron microscopy, concentrated VLPs were stained with 1% phosphotungstic acid. Bar, 100 nm. (c) For neuraminidase ﬂuorescence-based assay, VLPs were
initially diluted 10-fold (ﬁlled squares) or 100-fold (open triangles), or tested undiluted (open diamonds). Negative control (PBS) is indicated with open circles. Normalization
line is also shown (dashed). The NA enzymatic activity was measured in Relative Fluorescent Units (R.F.U.).
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VLPs in ferrets after intranasal vaccination
Ferrets represent highly relevant animal model for inﬂuenza
(Cheng et al., 2009; Huang et al., 2011; Perrone et al., 2009).
Ferrets received two vaccinations i.n. of the H5/H7/H9 triple-
subtype VLPs and control animals received PBS in place of vaccine.
The i.n. route was chosen because we previously showed that i.m.
vaccination with triple-subtype VLPs resulted in protective
responses (Pushko et al., 2011). There were no adverse effects
from the vaccine in ferrets and similar weight gains were observed
between vaccinated and PBS control animals (not shown). The
hemagglutination inhibition (HI) and virus neutralizing (VN) anti-
body responses to each homologous virus were measured in
individual serum samples collected prior to vaccine boost and
challenge. After the ﬁrst vaccine dose, HI antibody was elicited to
H7 (titer of 10) and H9 (titer range 20 to 80) antigens, whereas no
HI antibody was detected to H5 antigen. This is in line with prior
observations of low immunogenicity of H5 protein (Treanor et al.,
2006). As expected, no HI antibody was detected in control
animals. After boost vaccination, both HI and VN titers to all three
homologous viruses were detected in animals vaccinated with
triple-subtype VLPs, but not in control animals (Table 1). In the
sera from ferrets vaccinated with VLPs, the highest HI and VN
titers were observed to HK/09 virus, while the lowest antibody
titers were to VN/04 virus (Table 1). No HI antibody was detected
to heterologous H5N1 viruses A/Egypt/4935/09 (clade 2.2.1) and A/
Duck/Vietnam/1206/12 (clade 2.3.2.1) (data now shown).
Vaccine protection was measured by survival, reduction in
fever, weight loss, and viral shedding in ferrets following homo-
logous virus challenges. Although 106 EID50 challenges with H7N2
or H9N2 viruses did not result in a lethal outcome, PBS control
ferrets challenged with H5N1 virus, developed severe disease and
had to be euthanized on days 5–6 p.c. due to severe neurological
symptoms. In spite of the lowest pre-challenge HI and VN anti-
body titers to H5N1, all VLP-vaccinated animals survived challenge
with H5N1 virus (Table 1). H7N2 and H5N1 challenge viruses
induced an increase in body temperature among control ferrets
with mean maximum fever of 1.1 1C and 2.0 1C over baseline,
respectively (Table 1). The rise in body temperature among VLP
vaccinated ferrets after H7N2 and H5N1 challenge was less than
that of controls, with mean maximum fever of 0.3 1C and 0.6 1Cover baseline, respectively. In spite of the strong H9N2 HA and VN
response (Table 1), the difference in body temperatures of control
and vaccinated ferrets after H9N2 virus challenge was less appar-
ent and statistically not signiﬁcant. This was consistent with the
previous study, in which only part of H9N2-infected ferrets
showed transient elevation of temperature (Wan et al., 2008).
The triple-subtype VLPs also provided protection against
weight loss in H5N1 and H9N2 challenged groups. In particular,
on day 6 p.c., VLP-vaccinated ferrets lost 4.7% of starting weight
after challenge with H5N1 virus, compared with 13.4% weight
loss for the control ferrets (Table 1). Following challenge with
H9N2 virus, vaccinated ferrets lost 1.8% of weight, whereas control
animals lost 6.9% of their pre-challenge weight. The difference
in body weights of control and vaccinated ferrets after H7N2
virus challenge was less apparent; some control animals have
increased weight after challenge, however the differences were
not signiﬁcant.
The extent of virus replication in the upper respiratory tract
was determined by titrating nasal wash samples collected from
immune and control ferrets following challenge with homologous
virus. All three subtypes replicated efﬁciently in the upper
respiratory tract of unimmunized control ferrets for six days p.c.
(Fig. 3). In comparison, immunized animals displayed a signiﬁcant
reduction in H5N1, H7N2 and H9N2 viral load. Moreover, the
majority of VLP-immune ferrets cleared H5N1 and H7N2 virus two
days earlier than control ferrets. Taken together, these data
demonstrate that H5/H7/H9 triple-subtype VLP immunization via
i.n. route offered signiﬁcant protection against substantial fever,
weight loss, and viral shedding following homologous virus
challenge, as well as against severe neurological disease in case
of H5N1 virus infection.Discussion
Annual inﬂuenza epidemics affect millions of people world-
wide causing incapacitating illnesses that can result in hospitali-
zation or death, especially in the elderly, the very young and those
with underlying health conditions. Pandemic inﬂuenza represents
even a greater threat than seasonal epidemics. The “Spanish”
inﬂuenza of 1918 caused by H1N1 subtype virus was the most
devastating pandemic in the human history and responsible for
Table 1
Antibody responses and clinical signs of infection following challenge with A/Vietnam/1203/04 (H5N1), A/New York//107/03 (H7N2), or A/Hong Kong/33982/09
(H9N2) viruses.
Virus Vaccine status HI titer range (GMT)a VN titer range (GMT) Mean max temperature
increase (1C)
% Mean weight
loss b (t test)
Mean peak virus titer
(log10 EID or PFU/ml)
Survival
VN/04H5N1 VAX 5–10 (7.1) 10–20 (13.3) 0.6 4.7 (0.08) 3.9 4/4
PBS o10 o10 2.0 13.4 5.6 0/4c
NY/03H7N2 VAX 10–40 (23.8) 10–160 (35.6) 0.3 4.7 (0.47) 4.8 4/4
PBS o10 o10 1.1 2.3 6.1 4/4
HK/09H9N2 VAX 20–80 (33.6) 20–160 (63.5) 1.2 1.8 (0.01) 4.0 4/4
PBS o10 o10 0.7 6.9 6.2 4/4
a As measured in pre-challenge sera, turkey RBCs were used to assess antibody response to NY/03 and HK/09 viruses, horse RBCs were used to assess antibody response
to VN/04 virus.
b Measured at day 6 p.c.
c Two ferrets were euthanized on day 5 and two were euthanized on day 6 post challenge due to neurological symptoms.
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Taubenberger et al., 2012). Multiple potentially pandemic viruses
continue to circulate in birds and other animals. In particular,
avian inﬂuenza viruses of H5, H7, and H9 subtypes have been
identiﬁed as pathogens of concern and potentially pandemic
viruses (Belser et al., 2008; Palese, 2004; Pappas et al., 2007;
WHO, 2013). In addition to the potential of causing lethal human
disease and pandemics, avian inﬂuenza can cause devastating
epizootics in poultry that can threaten food supply and safety,
and also result in reduced capability to manufacture egg-
dependent vaccines worldwide including those against inﬂuenza,
yellow fever, mumps and measles viruses. Therefore, vaccines
capable of protecting against multiple potentially pandemic inﬂu-
enza strains are needed. Candidate vaccines against H5, H7,and H9
viruses have been prepared in the past (Couch et al., 2012). In
order to enhance pandemic preparedness, inactivated H5N1 vac-
cines have been developed and approved by regulatory agencies
(O'Neill and Donis, 2009) including recently approved cell culture-
derived Flucelvax vaccine. Both the VN/04 (H5N1) and HK/09
(H9N2) viruses are on the list of candidate vaccines recommended
by the World Health Organization (WHO) in 2012 for pandemic
preparedness (WHO, 2012a). However, although H7 and H9
candidate vaccine strains exist, there are currently no approved
vaccines available for human use for these subtypes (WHO, 2012a).
Recombinant multi-HA VLPs described in this study represent a
conceptually novel multi-speciﬁc inﬂuenza vaccine, which is
designed to elicit speciﬁc immunity to H5, H7, and H9 inﬂuenza
strains and does not require blending of individual vaccines to
prepare a trivalent formulation. Previously, we have shown by
immunoelectron microscopy that multi-subtype VLP co-localize
multiple subtypes of hemagglutinin within the same particle, thus
acquiring capability to protect against multiple inﬂuenza viruses
following i.m. vaccination (Pushko et al., 2011). In the current
study, we showed that H5/H7/H9 triple-subtype VLPs combine
neutralizing epitopes from three inﬂuenza subtypes and protect
from three potentially pandemic viruses even when administered
mucosally.
Alternative approaches for preparation of broadly protective
inﬂuenza vaccine include blended trivalent vaccine formulations
as well as the “universal” vaccine approaches involving consensus
sequences of HA protein or highly conserved inﬂuenza epitopes,
for example the ectodomain of M2 ion channel protein (Denis
et al., 2008; Ebrahimi et al.; Schotsaert et al., 2009). Universal
vaccine approaches also include induction of immune response to
conserved regions of HA (Pica and Palese, 2013; Rao et al., 2010;
Wang and Palese, 2009; Wei et al., 2010). Our results suggest that
in addition to blended trivalent and universal vaccine approaches,
the multi-subtype VLPs can also induce immune responses and
protection against multiple inﬂuenza viruses following i.m. and i.n.
vaccinations. Similarly to the previously reported i.m. vaccination(Pushko et al., 2011), the protection observed in the current study
in mucosally vaccinated ferrets is likely due to the production of
virus-neutralizing antibodies directed against the HA. Although
neutralizing antibody levels to H5N1 virus were low (10–20),
mucosally vaccinated animals were protected against death fol-
lowing a lethal H5N1 virus challenge. Other immune responses
not measured in the present study, in particular mucosal and
T-cell-mediated immunity, may have contributed to protection
(Nguyen et al., 1999; Pillet et al., 2011; Tumpey et al., 2001).
Assessments in vivo of mucosal immune functions following
inﬂuenza virus infection have been limited owing to a lack of
ferret-speciﬁc reagents and incomplete genome sequencing of this
species. Furthermore, the present proof-of-concept study was
focused on detection of shedding virus in the nasal secretions
and not designed for reliable evaluation of mucosal IgG and IgA.
Detailed evaluation of mucosal IgG and IgA responses including
heterosubtypic immunity in the i.n. vaccinated animals will be
addressed in a separate study.
Since this is a novel approach, additional research and pre-
clinical testing is needed. It is not known at this time if distinct HA
subtypes form homo- or heterotrimers on the surface of VLPs.
Previous research suggested that mixed trimers are not formed
between the HAs of distinct subtypes and that incorrectly folded
HA molecules are excluded during intracellular transport and
exocytosis (Boulay et al., 1988; Chao, 1992). Furthermore, future
studies will include development of quantitation methods for each
HA subtype within triple-subtype VLPs. For this purpose, the
single radial immunodiffusion (SRID) test recommended by the
Center for Biologics Evaluation and Research (CBER) can be
employed. These studies are hampered by unavailability of
reagents to H7 and H9 subtypes and will be accomplished when
reference standards become available. Previous electron micro-
scopy and SRID studies on triple-subtype VLPs containing seasonal
inﬂuenza subtypes have shown that distinct HA subtypes are co-
localizing within multi-subtype VLPs at approximately equivalent
quantities (Pushko et al., 2011). In case if certain HA subtypes
require higher quantities for optimal immunogenicity, their pre-
sence within multi-subtype VLPs can potentially be improved by
genetic engineering. For example, incorporation of HIV env protein
into VLPs could be improved more than 10-fold by the rational
design of leader and transmembrane domains of env (Wang et al.,
2007). Additional data are also needed regarding protective effects
of triple-subtype VLPs against heterologous challenges. It has been
previously shown that mucosally vaccinated ferrets have broader
protection against challenge with unrelated strains than parent-
erally vaccinated animals (Perrone et al., 2009). In summary, the
current study shows that triple-subtype H5/H7/H9 VLPs can be a
promising option for prepandemic vaccine that can be stockpiled
and in the case of a pandemic involving either H5, H7 or H9 avian
inﬂuenza viruses, could be used as a ﬁrst line defense during the
Fig. 3. Virus titers in the nasal cavities of VN/04 or NY/03 or HK/09—challenged
ferrets previously inoculated with triple-subtype VLPs or PBS. Twelve ferrets were
vaccinated intranasally (i.n.) with 15 μg (based on HA content) of triple-subtype
VLPs two times, ﬁve weeks apart and randomly assigned to groups for virus
challenge. Control ferrets were inoculated with PBS on the same schedule as
vaccinated ferrets. Vaccinated and PBS-control ferrets were challenged with 106
EID50 VN/04 (H5N1) virus or 106 EID50 NY/03 (H7N2) virus or 106 PFU HK/09
(H9N2) virus. Nasal cavities of all ferrets were washed with 1ml PBS every other
day starting two days p.c. and titrated in either eggs or standard plaque assay;
averages of all four ferrets in each group are reported, error bars represent standard
deviation. Open bars represent vaccinated ferrets, ﬁlled bars represent PBS-control
ferrets, dotted lines indicate limit of detection for titration in eggs (top and middle
panel) or plaque assay (bottom panel). Signiﬁcant differences in titers between
vaccinated and PBS-control groups, as analyzed by Student's t-test, are marked with
an asterisk (*p≤0.045).
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pandemic virus. If proven safe and efﬁcacious, this generic
approach can also be applicable to other inﬂuenza viruses includ-
ing seasonal strains.Materials and methods
Viruses, plasmids and cells
Inﬂuenza HA gene sequences were derived from A/Viet Nam/
1203/2004 (H5N1), A/New York/107/2003 (H7N2) and A/Hong
Kong/33982/2009 (H9N2) viruses, further designated VN/04, NY/03, and HK/09, respectively. The sequences for HA genes were
from the GenBank accession no. ABP51977.1, ACC55270.1 and
ADC41843.1, respectively. All three HA genes were codon-
optimized and synthesized (Genscript, Piscataway, NJ) for high-
level expression in Spodoptera frugiperda (Sf9) cells (ATCC,
Manassas, VA). The NA and M1 gene sequences, GenBank
CY105898.1 and V01099.1, respectively, were derived from A/Puerto
Rico/8/1934 (H1N1) virus, further designated PR8. In order to
generate triple-subtype pandemic VLPs, three full-length HA genes,
as well as NA and M1 genes were cloned within a single baculovirus
vector, each gene within its own transcriptional cassette that
included a polyhedrin promoter upstream from each gene. Recom-
binant baculovirus (rBV) expressing H5, H7, H9, NA, and M1 genes
was generated using a Bac-to-Bac baculovirus expression system
(Life Technologies, Carlsbad, CA). The titers of rBV preparations
were determined by standard plaque assay in Sf9 cells.
Preparation of triple-subtype H5/H7/H9 VLPs
Sf9 cells were maintained as suspension cultures in SF900II-
SFM insect serum free medium (Life Technologies, Carlsbad, CA) at
27 1C. For production of H5/H7/H9 VLPs, Sf9 cells were adjusted to
2106 cells/ml and infected at a multiplicity of infection (MOI) of
3.0 for 72 h with rBV expressing H5, H7, H9, NA and M1 genes.
Immunoﬂuorescense assay (IFA) was done using ferret antisera
speciﬁc for H5, H7, and H9 inﬂuenza (CDC, Atlanta, GA). For
ﬂuorescent staining, 0.3 ml aliquots of infected Sf9 cells were
seeded into eight-well Nunc LabTek slides. Following 72 h incuba-
tion at 27 1C, Sf9 cells were ﬁxed with cold acetone, and IFA was
carried out as described elsewhere (Pushko et al., 2001). Antigen-
expressing cells were visualized using FITC-conjugated goat anti-
ferret IgG (H+L) (KPL, Gaithersburg, MD). VLPs were harvested
from the growth medium supernatant, concentrated and partially
puriﬁed by using a 20% (w/v) sucrose step gradient in phosphate
buffered saline (PBS). VLPs were stored at 2–8 1C in a PBS buffer
until vaccinations. The SDS-PAGE was done in 4–12% polyacryla-
mide gels (Life Technologies, Carlsbad, CA) followed by staining
with GelCode Blue stain (Pierce, Rockford, IL). Western blots were
carried out by using ferret subtype-speciﬁc antisera followed by
alkaline phosphatase-conjugated goat anti-ferret IgG (H+L). The
HA content was estimated by determining total protein concen-
tration using ﬂuorometric method (Qubit 2.0, Life Technologies)
followed by densitometry analysis of stained gel and calculating
total HA protein content from the percentage of the HA bands.
Hemagglutination and neuraminidase assays
For hemagglutination assay, VLPs were serially diluted at 2-fold
increments in 50 μl volume in a 96-well plate. To each VLP
dilution, 50 μl of 0.5% turkey red blood cell (RBC) working solution
was added, mixtures of VLPs and RBCs were gently agitated and
the plate was incubated at room temperature for 30–60 min
before examination. Negative hemagglutination results appeared
as dots in the center of the wells. The titer was calculated as the
highest dilution factor that produced a positive reading. The
functional neuraminidase enzymatic activity was determined by
using a ﬂuorescence-based NA assay (NA-Fluor, Life Technologies)
with methyl umbelliferone N-acetyl neuraminic acid (MUNANA;
Sigma, St Louis, MO) as a substrate according to manufacturer's
instructions. Diluent (saline) was used as a negative control.
Electron microscopy of H5/H7/H9 VLPs
VLP samples were adsorbed onto a freshly discharged 400 mesh
carbon parlodion-coated copper grids (Poly-Sciences, Warrington,
PA). The grids were rinsed with buffer containing 20 mM Tris,
I. Tretyakova et al. / Virology 442 (2013) 67–7372pH 7.4, and 120 mM KCl and negatively stained with 1% phospho-
tungstic acid, then dried by aspiration. VLPs were visualized on a
Hitachi H-7600 transmission electron microscope (Hitachi High
Technologies America, Schaumburg, IL) operating at 80 kV and
digitally captured with a CCD camera at 1 k1 k resolution
(Advanced Microscopy Techniques Corp., Danvers, MA).Serological assays.
All sera were initially diluted 1:10 in receptor-destroying enzyme
from Vibrio cholerae (Denka Seiken, Tokyo, Japan). Hemagglutination
inhibition (HI) assay was performed using 0.5% turkey or 1% horse
erythrocytes with 4 HA units of homologous viruses using standard
methods (Pushko et al., 2005). Horse RBCs were used to assess HI
antibody response to VN/04 virus. Titers of virus neutralizing (VN)
antibody were determined essentially as described (Mozdzanowska
et al., 1997) and expressed as the reciprocal of the highest dilution of
serum that neutralized 100–200 plaque forming units of virus in
MDCK cell cultures. The neutralization titers were also presented as
the geometric mean titers (GMT) from vaccinated or control ferrets.Viruses for ferret challenge.
The virus stocks of VN/04 and NY/03 were grown in the
allantoic cavities of ten-day-old embryonated hens' eggs at 37 1C
for 24–26 or 40 h, respectively. The virus stock of HK/09 was
grown in Madin–Darby Canine Kidney (MDCK) cells as previously
described (Zeng et al., 2007). Pooled allantoic ﬂuid or cell super-
natant was clariﬁed by centrifugation and aliquots were stored at
−70 1C until use. A 50% egg infectious dose (EID50/ml) and plaque
forming unit (PFU) titers in MDCK cells were determined using
standard assay methods as previously described (Zeng et al.,
2007). All experiments were performed in negative pressure
biosafety level 3 laboratories with enhancements as outlined in
the Biomedical Microbiological and Biomedical Laboratory.Ferret vaccination and viral challenge
Adult male Fitch ferrets, 4 to 5 months of age (Triple F Farms,
Sayre, PA), serologically negative by HI assay for currently circulat-
ing inﬂuenza viruses, were used in this study. For vaccinations,
ferrets were each inoculated 2 times (5 weeks between inocula-
tions) intranasally (i.n.) with 15 μg of total HA in the VLPs
(vaccinated) or with PBS (controls). The vaccine dose of 15 μg
and route of administration were consistent with the previous
human clinical trial of puriﬁed HA antigen (Stephenson et al.,
2006). Prior to primary vaccination, vaccine boost, and viral
challenge, all ferrets were bled for collection of serum to assess
response to vaccination and randomly assigned for challenge with
VN/04 virus, NY/03 virus, or HK/09 virus (4 vaccinated and 4 PBS
controls for each challenge group). Following anesthesia with an
intramuscular injection of a ketamine–xylazine–atropine cocktail,
ferrets were challenged i.n. with 106 EID50 (VN/04 and NY/03) or
106 PFU (HK/09) of virus in a total volume of 1 ml (500 μl per
nostril) diluted in PBS. Viral challenge occurred 5.5 to 7.5 weeks
after vaccine boost. Following challenge, ferrets were monitored
daily for changes in body weight and temperature, as well as
clinical signs of illness. Nasal wash samples were collected at 2, 4,
6, and 8 days post-challenge (p.c.) and titrated in eggs (VN/04 and
NY/03) or in a standard plaque assay (HK/09) to determine viral
titers in the upper respiratory tract. The statistical signiﬁcance of
differences in weight loss, temperature changes, and virus titers
between vaccinated and PBS-control animals were determined by
Student's t test.Acknowledgments
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